# Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

> **NCT04521114** · PHASE2 · COMPLETED · sponsor: **CytoDyn, Inc.** · enrollment: 87 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** Placebo
- **DRUG:** leronlimab 700 mg
- **DRUG:** leronlimab 350 mg

## Key facts

- **NCT ID:** NCT04521114
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2021-12-29
- **Final completion:** 2021-12-29
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521114, "Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04521114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*